Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Proto

Showing results (501-510 of 595) with videos related to

Pageof 60
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access programArsela Prelaj, Achille Bottiglieri, Claudia Proto, et al.
Tumori|February 19, 2024
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% FundLuigi Cerbone, Sara Delfanti, Stefania Crivellari, et al.
Scientific Reports|September 7, 2023
Microbial signature of plaque and gut in acute coronary syndromeEugenia Pisano, Francesca Bugli, Anna Severino, et al.
Cancer Cell|October 22, 2020
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT ExperienceAnnalisa Trama, Claudia Proto, Jennifer G Whisenant, et al.
Clinical Lung Cancer|November 9, 2020
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab MonotherapyGiannis Mountzios, Alessandro de Toma, Panagiota Economopoulou, et al.
Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association|June 22, 2011
Insights on PRAME and osteosarcoma by means of gene expression profilingSílvia Regina Caminada Toledo, Marco Antonio Zago, Indhira Dias Oliveira, et al.
BMJ Open|May 16, 2025
Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: real-world observational studyValentina De Micheli, Luca Agnelli, Elena Conca, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2021
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkersRiccardo Lobefaro, Giuseppe Viscardi, Raimondo Di Liello, et al.
Critical Reviews in Oncology/Hematology|February 3, 2025
Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION groupChiara Catania, Claudia Proto, Chiara Bennati, et al.
Clinical Lung Cancer|April 16, 2020
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External ValidationArsela Prelaj, Giuseppe Lo Russo, Claudia Proto, et al.
Pageof 60

Showing results (501-510 of 595) with videos related to

Sort By:
Pageof 60
European Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access programArsela Prelaj, Achille Bottiglieri, Claudia Proto, et al.
Tumori|February 19, 2024
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% FundLuigi Cerbone, Sara Delfanti, Stefania Crivellari, et al.
Scientific Reports|September 7, 2023
Microbial signature of plaque and gut in acute coronary syndromeEugenia Pisano, Francesca Bugli, Anna Severino, et al.
Cancer Cell|October 22, 2020
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT ExperienceAnnalisa Trama, Claudia Proto, Jennifer G Whisenant, et al.
Clinical Lung Cancer|November 9, 2020
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab MonotherapyGiannis Mountzios, Alessandro de Toma, Panagiota Economopoulou, et al.
Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association|June 22, 2011
Insights on PRAME and osteosarcoma by means of gene expression profilingSílvia Regina Caminada Toledo, Marco Antonio Zago, Indhira Dias Oliveira, et al.
BMJ Open|May 16, 2025
Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: real-world observational studyValentina De Micheli, Luca Agnelli, Elena Conca, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2021
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkersRiccardo Lobefaro, Giuseppe Viscardi, Raimondo Di Liello, et al.
Critical Reviews in Oncology/Hematology|February 3, 2025
Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION groupChiara Catania, Claudia Proto, Chiara Bennati, et al.
Clinical Lung Cancer|April 16, 2020
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External ValidationArsela Prelaj, Giuseppe Lo Russo, Claudia Proto, et al.
Pageof 60